That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Atria Investments Inc cut its holdings in GSK plc (NYSE:GSK – Free Report) by 7.6% in the fourth quarter, according to the ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

M&T Bank Corp cut its position in GSK plc (NYSE:GSK – Free Report) by 10.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned ...

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

GSK reported core earnings of 59 cents per American ... driven by strong patient demand for Jemperli and Ojjaara Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely ...